Table 1.
Detailed patient and tumour characteristics. Hormone receptor status and HER2 receptor status are indicated for each in situ and invasive tumour component. ER+, oestrogen receptor‐positive; ER−, oestrogen receptor‐negative; ID, patient pseudonym; NAC, neoadjuvant chemotherapy; NST, invasive carcinoma of no special type; PR+, progesterone receptor‐positive; PR−, progesterone receptor‐negative.
| ID | Patient age at diagnosis (years) | Nottingham grade | Invasive tumour size (mm) a | Tumour and node stage | DCIS grade | Analysed specimen | NAC |
In situ component Hormone receptor status |
Invasive component Hormone receptor status |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HER2‐negative | HER2‐positive | HER2‐negative | HER2‐positive | ||||||||
| 1 | 50 | 3 | 7 | pT1bN0 | 3 | Resection | No |
DCIS ER− PR− |
DCIS ER− PR− |
– |
MC ER− PR− |
| 2 | 35 | 3 | 16 | ypT1c(2) N0 | 3 | Resection | Yes b | – |
DCIS ER− PR− |
NST ER+ PR+ |
NST ER− PR− |
| 3 | 51 | 2 | 15 | pT1c N0 | – | Resection | No |
LCIS ER+ PR+ |
LCIS ER+ PR+ |
ILC ER+ PR+ |
– |
| 4 | 51 | 2 | 11 | pT1c N0(i+) | 3 | Resection | No | – |
DCIS ER+ PR+ |
NST ER+ PR+ |
NST ER+ PR+ |
| 5 | 55 | 3 | 24 | pT2 N1a | 3 | Resection | No |
DCIS ER+ PR+ |
– |
NST ER+ PR+ |
NST ER+ PR+ |
| 6 | 50 | 2 | 12 | ypT1c N0 | 3 | Biopsy | Yes | – |
DCIS c ER+ PR− |
NST ER+ PR+ |
NST ER− PR− |
| 7 | 51 | 1 | 21 | pT2 N0 | 2 | Resection | No | – |
DCIS ER+ PR− |
NST ER+ PR+ |
– |
| 8 | 56 | 3 | 18 | pT1c N0 | 3 | Resection | No |
DCIS ER+ PR+ |
DCIS ER+ PR− |
NST ER+ PR |
NST ER+ PR− |
| 9 | 55 | 2 | 18 | pT1c N1(mi) | 3 | Resection | No |
DCIS c ER+ PR+ |
DCIS ER+ PR |
NST ER+ PR+ |
– |
| 10 | 42 | 3 | 19 | pT1c N2b | 3 | Resection | No | – |
DCIS ER− PR− |
NST ER− PR− Axillary metastasis ER− PR− |
– |
As measured in the resection specimen.
Miller–Payne response grade 3
Single duct, which disappeared during tissue sectioning; not included in this study because of insufficient material for targeted sequencing.